{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:11:42Z","timestamp":1779246702871,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Molnupiravir and nirmatrelvir-ritonavir were the first oral antiviral agents to demonstrate reduced hospitalization or death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but patients with immunocompromised conditions were not well-represented. The objective of this study was to characterize and compare the clinical outcomes of US veterans with immunocompromised conditions prescribed oral antivirals with those who did not receive oral antivirals for mild-to-moderate SARS-CoV-2 active infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, observational, nationwide propensity-matched analysis of US veterans with immunocompromised conditions who developed documented SARS-CoV-2 infection. The primary outcome was the composite of any hospitalization or death within 30 days of diagnosis. Secondary outcomes included 30-day comparative rates of (1) any hospitalization, (2) death, (3) intensive care requirement, and (4) subset analyses of outcomes by oral antiviral used and vaccination status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The composite primary outcome was significantly lower in patients receiving oral antiviral therapy compared with those who did not (23\/390 [5.9%] vs 57\/390 [14.6%]; odds ratio, 0.37; 95% confidence interval, .22\u2013.61). This difference was driven largely by fewer deaths in the oral antiviral group (1\/390 [0.3%] vs 19\/390 [4.9%]; odds ratio, 0.05; 95% confidence interval, .007\u2013.38). There was no significant difference in rate of intensive care requirement. The composite outcome was improved in vaccinated patients (completing the first series or first booster dose) who received oral antiviral agents compared with those who did not receive oral antiviral agents. Compared with those prescribed nirmatrelvir-ritonavir, patients given molnupiravir were older, had a higher incidence of cautions\/contraindications, greater prevalence of tobacco use, and more cardiovascular complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Use of molnupiravir or nirmatrelvir-ritonavir was associated with lower incidences of hospitalization or death within 30 days of diagnosis in US veterans with immunocompromised conditions, regardless of vaccination status. These findings support the use of either oral antiviral in this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad504","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:55:57Z","timestamp":1692813357000},"page":"330-337","source":"Crossref","is-referenced-by-count":7,"title":["Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents"],"prefix":"10.1093","volume":"78","author":[{"given":"Chris A","family":"Gentry","sequence":"first","affiliation":[{"name":"Chief of Pharmacy, Pharmacy Service, Oklahoma City Veterans Affairs Health Care System , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-1320","authenticated-orcid":false,"given":"Phoi N","family":"Nguyen","sequence":"additional","affiliation":[{"name":"PGY2 Infectious Diseases Pharmacy Resident, Pharmacy Service, Oklahoma City Veterans Affairs Health Care System , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharanjeet K","family":"Thind","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section Chief, Medical Service, Oklahoma City Veterans Affairs Health Care System , Oklahoma City, Oklahoma , USA"},{"name":"Department of Medicine, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Kurdgelashvili","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma , USA"},{"name":"Chief of Medicine, Medical Service, Oklahoma City Veterans Affairs Health Care System , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Riley J","family":"Williams","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Pharmacy Service, Oklahoma City Veterans Affairs Health Care System , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"2024021719323508200_ciad504-B1","author":"World Health Organization COVID-19 dashboard"},{"key":"2024021719323508200_ciad504-B2","doi-asserted-by":"crossref","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2024021719323508200_ciad504-B3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","article-title":"Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States","volume":"40","author":"Gupta","year":"2021","journal-title":"Health Aff"},{"key":"2024021719323508200_ciad504-B4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14760584.2022.2035222","article-title":"COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies","volume":"21","author":"Di Fusco","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"2024021719323508200_ciad504-B5","author":"COVID-19 Treatment Guidelines Panel"},{"key":"2024021719323508200_ciad504-B6","author":"United States Food and Drug Administration"},{"key":"2024021719323508200_ciad504-B7","author":"United States Food and Drug Administration"},{"key":"2024021719323508200_ciad504-B8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"2024021719323508200_ciad504-B9","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2024021719323508200_ciad504-B10","author":"United States Department of Veterans Affairs"},{"key":"2024021719323508200_ciad504-B11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2023.01.018","article-title":"Characteristics and outcomes of US veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents","volume":"86","author":"Gentry","year":"2023","journal-title":"J Infect"},{"key":"2024021719323508200_ciad504-B12","doi-asserted-by":"crossref","first-page":"e689","DOI":"10.1016\/S2665-9913(20)30305-2","article-title":"Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective, propensity analysis study","volume":"2","author":"Gentry","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024021719323508200_ciad504-B13","author":"United States Department of Veterans Affairs"},{"key":"2024021719323508200_ciad504-B14","author":"United States Food and Drug Administration"},{"key":"2024021719323508200_ciad504-B15","author":"United States Food and Drug Administration"},{"key":"2024021719323508200_ciad504-B16","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/ajt.17098","article-title":"Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge","volume":"22","author":"Radcliffe","year":"2022","journal-title":"Am J Transplant"},{"key":"2024021719323508200_ciad504-B17","first-page":"1","article-title":"Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial","author":"Johnson","year":"2023","journal-title":"Infection"},{"key":"2024021719323508200_ciad504-B18","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.15585\/mmwr.mm7148e2","article-title":"Paxlovid associated with decreased hospitalization rate among adults with COVID-19\u2014United States, April\u2013September 2022","volume":"71","author":"Shah","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024021719323508200_ciad504-B19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","article-title":"Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system","volume":"23","author":"Lewnard","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024021719323508200_ciad504-B20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad504\/51698783\/ciad504.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/330\/56697864\/ciad504.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/2\/330\/56697864\/ciad504.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T19:33:05Z","timestamp":1708198385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/2\/330\/7250437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8,24]]},"published-print":{"date-parts":[[2024,2,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad504","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,15]]},"published":{"date-parts":[[2023,8,24]]}}}